Skip to main content
    S

    Stryker Corporation (SYK)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $293.32
    +11.70 (+4.15%)

    Market Cap: $108.02B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    85%(33/39)
    Avg Surprise
    +3.57%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$3.56
    Range$3.44 - $3.80
    25 analysts
    EPS RevisionsNo revisions (7d)
    0
    12
    30d
    EPS Estimate DriftChange to current
    90d ago$3.69-3.4%
    60d ago$3.60-0.9%
    30d ago$3.59-0.7%
    7d ago$3.57-0.2%
    Current$3.56
    Revenue Consensus
    $6.6B
    Range$6.5B - $6.7B
    25 analysts
    Period ending Dec 31, 2026
    EPS Consensus$4.94
    Range$4.86 - $5.04
    28 analysts
    Revenue Consensus
    $7.7B
    Range$7.5B - $7.8B
    27 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$4.94---
    Sep 26EST
    		-$3.56---
    Jun 26
    Reported Jul 30
    		$3.69$3.46+6.65%Beat+17.9%
    Mar 26
    Reported Apr 30
    		$2.60$2.98-12.75%Miss-8.5%
    Dec 25
    Reported Jan 29
    		$4.47$4.40+1.59%Beat+11.5%
    Sep 25
    Reported Oct 30
    		$3.19$3.13+1.92%Beat+11.1%
    Jun 25
    Reported Jul 31
    		$3.13$3.07+1.95%Beat+11.4%
    Mar 25
    Reported May 1
    		$2.84$2.73+4.03%Beat+13.6%
    Dec 24
    Reported Jan 28
    		$4.01$3.87+3.62%Beat+15.9%
    Sep 24
    Reported Oct 29
    		$2.87$2.77+3.61%Beat+16.7%
    Jun 24
    Reported Jul 30
    		$2.81$2.79+0.72%Beat+10.6%
    Mar 24
    Reported Apr 30
    		$2.50$2.36+5.93%Beat+16.8%
    Dec 23
    Reported Jan 30
    		$3.46$3.27+5.81%Beat+15.3%
    Sep 23
    Reported Nov 2
    		$2.46$2.44+0.82%Beat+16.0%
    Jun 23
    Reported Aug 3
    		$2.54$2.38+6.72%Beat+12.9%
    Mar 23
    Reported May 1
    		$2.14$2.00+7.00%Beat+8.6%
    Dec 22
    Reported Jan 31
    		$3.00$2.84+5.63%Beat+10.7%
    Sep 22
    Reported Oct 31
    		$2.12$2.23-4.93%Miss-3.6%
    Jun 22
    Reported Jul 26
    		$2.25$2.28-1.32%Miss+0.0%
    Mar 22
    Reported Apr 28
    		$1.97$1.92+2.60%Beat+2.1%
    Dec 21
    Reported Jan 27
    		$2.71$2.72-0.37%Miss-3.6%
    Sep 21
    Reported Oct 28
    		$2.20$2.28-3.51%Miss+2.8%
    Jun 21
    Reported Jul 27
    		$2.25$2.13+5.63%Beat+251.6%
    Mar 21
    Reported Apr 27
    		$1.93$1.98-2.53%Miss+4.9%
    Dec 20
    Reported Jan 27
    		$2.81$2.55+10.20%Beat+12.9%
    Sep 20
    Reported Oct 29
    		$2.14$1.43+49.65%Beat+12.0%
    Jun 20
    Reported Jul 30
    		$0.64$0.57+12.28%Beat-67.7%
    Mar 20
    Reported Apr 30
    		$1.84$1.74+5.75%Beat-2.1%
    Dec 19
    Reported Jan 28
    		$2.49$2.46+1.22%Beat+14.2%
    Sep 19
    Reported Oct 29
    		$1.91$1.90+0.53%Beat+13.0%
    Jun 19
    Reported Jul 25
    		$1.98$1.94+2.06%Beat+12.5%
    Mar 19
    Reported Apr 23
    		$1.88$1.84+2.17%Beat+11.9%
    Dec 18
    Reported Jan 29
    		$2.18$2.15+1.40%Beat+11.2%
    Sep 18
    Reported Oct 25
    		$1.69$1.68+0.60%Beat+11.2%
    Jun 18
    Reported Jul 24
    		$1.76$1.73+1.73%Beat+15.0%
    Mar 18
    Reported Apr 26
    		$1.68$1.60+5.00%Beat+13.5%
    Dec 17
    Reported Jan 30
    		$1.96$1.95+0.51%Beat+10.1%
    Sep 17
    Reported Oct 26
    		$1.52$1.50+1.33%Beat-
    Jun 17
    Reported Jul 27
    		$1.53$1.51+1.32%Beat-
    Mar 17
    Reported Apr 25
    		$1.48$1.43+3.50%Beat-
    Dec 16
    Reported Jan 24
    		$1.78$1.76+1.14%Beat-

    Dividends

    Dividend Metrics

    Forward Yield1.20%
    Forward Annual Dividend$3.52
    Payout Ratio24.43%
    FrequencyQuarterly
    Pay MonthsJan, Apr, Jul, Oct

    Growth

    3Y CAGR+6.25%
    5Y CAGR+7.62%
    SYK dividend history and ex-dividend datesRun SYK in the free DRIP calculator

    Key Metrics

    Valuation
    P/E Ratio21.03EV/EBITDA17.07x
    Price/FCF23.92xFCF Yield4.18%
    Profitability
    Profit Margin14.40%Operating Margin27.00%
    ROE16.50%ROIC11.25%
    Financial Health
    Debt/Equity0.62xInterest Coverage8.44x
    Current Ratio2.16xQuick Ratio1.33x
    Trading Statistics
    Beta0.78Avg Volume2.61M
    52-Week High$388.2552-Week Low$266.16

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$280.86
    SMA 20$277.20
    SMA 50$300.06
    SMA 200$325.70
    EMA 10$281.94
    EMA 20$282.17
    EMA 50$293.39
    EMA 200$320.93

    MACD

    Line: -2.78Signal: -5.96Hist: 3.18

    ADX

    ADX: 20.5+DI: 25.6-DI: 17.1

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down4.0
    PSAR$269.43

    Bollinger Bands

    Upper Band$288.39
    Lower Band$266.01
    %B Position807%(Upper)
    Band Width1.22

    RSI (14-Day)

    Neutral
    58.1

    Momentum Oscillators

    Stoch %K80.0
    Stoch %D74.0
    Williams %R-2.8
    ROC (10d)7.5%
    Momentum20.36
    CCI (20d)265.9
    MFI (14d)55.7

    Volatility Measures

    ATR (14d)$8.14(2.8%)
    StdDev (20d)5.59
    Hist Vol26.1%(Moderate)

    Volume Flow

    VWAP$291.28
    OBV-31.2M
    AD Line-305.2M
    CMF (20d)-0.214

    Volume Metrics

    Avg Vol (20d)2.6M
    Vol Ratio1.2x
    VWMA (20d)$277.30

    Pivot Points

    R3$292.41
    R2$289.04
    R1$285.33
    Pivot Point$281.95
    S1$278.24
    S2$274.87
    S3$271.16

    Advanced Oscillators

    TSI-10.13
    Ultimate Osc56.1
    KST-55.18

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$6.59B$6.02B$7.17B$6.06B$6.02B$5.87B$6.44B$5.49B$5.42B$5.24B$5.82B$4.91B
    Cost of Revenue$2.09B$2.21B$2.54B$2.21B$2.18B$2.12B$2.26B$1.98B$2.01B$1.91B$2.11B$1.75B
    Gross Profit$4.50B$3.81B$4.63B$3.85B$3.84B$3.74B$4.17B$3.52B$3.42B$3.33B$3.70B$3.16B
    Operating Expenses$2.84B$2.87B$2.82B$2.72B$2.73B$2.91B$3.59B$2.43B$2.37B$2.36B$2.45B$2.23B
    R&D$434.00M$413.00M$401.00M$410.00M$407.00M$405.00M$358.00M$377.00M$363.00M$368.00M$350.00M$353.00M
    SG&A$2.23B$2.28B$2.23B$2.04B$2.08B$2.30B$2.12B$1.89B$1.83B$1.84B$1.91B$1.71B
    Operating Income$1.66B$936.00M$1.80B$1.14B$1.11B$837.00M$581.00M$1.08B$1.05B$972.00M$1.26B$931.00M
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$141.00M$148.00M$99.00M$106.00M$159.00M$137.00M$53.00M$42.00M$53.00M$49.00M$31.00M$62.00M
    Income Before Tax$1.56B$850.00M$1.71B$1.03B$1.02B$764.00M$528.00M$1.04B$998.00M$923.00M$1.23B$869.00M
    Income Tax Expense$288.00M$105.00M$856.00M$170.00M$132.00M$110.00M$-18,000,000$209.00M$173.00M$135.00M$83.00M$177.00M
    Net Income$1.28B$745.00M$849.00M$859.00M$884.00M$654.00M$546.00M$834.00M$825.00M$788.00M$1.14B$692.00M
    EBITDA$2.00B$1.30B$2.63B$1.34B$1.47B$1.17B$1.20B$1.31B$1.26B$1.18B$1.84B$1.13B
    EBIT$1.71B$998.00M$2.31B$1.03B$1.18B$901.00M$937.00M$1.04B$998.00M$923.00M$1.59B$869.00M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    The Aristocrat Nobody Wanted: Why (MDT) Is Worth a Second Look Right Now

    (MDT) has raised its dividend for 48 consecutive years, yet trades at just 14x forward earnings. On a trailing basis it is 24x vs. (ISRG) at 57x and (SYK) at 40x. The 5-year dividend CAGR is 4.4%, slowing to 2.0% over three years. This is a yield anchor at 3.3%...

    Glenn Ford
    •
    4/8/26
    •
    157
    dividend aristocrats, value investing, Medical Devices
    Also mentions:
    ISRGABTSYK

    Why TransMedics Stock is a Buy for Long-Term Investors

    TransMedics is replacing a 60-year-old organ-transport method with its FDA-approved OCS platform, which keeps hearts, lungs, and livers alive and functioning during transit — a massive step-change in reliability and outc Business model now prints cash...

    Glenn Ford
    •
    11/14/25
    •
    285
    medical-technology, healthcare-innovation, organ-transplant, growth-stocks
    Also mentions:
    ISRGSYKMDTABTEW

    Government Contracts

    Gov Obligations (TTM)
    $74.47M
    Gov Obligations / Revenue
    0.3%
    Obligations YoY
    9.3%
    Active Awards
    5,562
    New Awards (TTM)
    5,479
    Avg Remaining Term
    8.6 mo

    Top agency: Department of Defense at 74.8% of trailing twelve month obligations across 6 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C24426N0793Department of Veterans AffairsDepartment of Veterans Affairs$5.60MJun 30, 2026
    36C25926N0341Department of Veterans AffairsDepartment of Veterans Affairs$1.75MJun 22, 2026
    36C24526N0738Department of Veterans AffairsDepartment of Veterans Affairs$1.19MJul 16, 2026
    36C25026N0391Department of Veterans AffairsDepartment of Veterans Affairs$1.07MMar 10, 2026
    36C26126P0453Department of Veterans AffairsDepartment of Veterans Affairs$990000Feb 25, 2026
    SPE2D625F2NADDepartment of DefenseDefense Logistics Agency$920000Sep 4, 2025
    70US0926F2GSA2360Department of Homeland SecurityU.S. Secret Service$517447Jun 5, 2026
    36C24826N0538Department of Veterans AffairsDepartment of Veterans Affairs$480000May 1, 2026
    36C24426F0234Department of Veterans AffairsDepartment of Veterans Affairs$311438Jul 22, 2026
    SPE2D626F4V3GDepartment of DefenseDefense Logistics Agency$307850Apr 10, 2026

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Abbott Laboratories stock: TD Cowen sets a USD 135.00 target for Abbott Laboratories stock

    TD Cowen has reiterated a Buy rating and set a USD 135.00 target price for Abbott Laboratories stock, anticipating third-quarter revenue of USD 13.00 billion and earnings per share of USD 1.42. The stock was trading at...

    ad-hoc-news.de•10/16/26•Neutral

    ISRG Ahead of Q3 Earnings: Can Procedure Growth Sustain Momentum?

    Intuitive Surgical (ISRG) is set to announce its Q3 2026 earnings, with expectations of continued adoption of its robotic-assisted surgery platforms despite moderating U.S. procedure growth and competitive pressures...

    The Globe and Mail•10/16/26•Neutral

    Intuitive Surgical stock carries a 48.7 P/ E on October 15, 2026

    Intuitive Surgical (ISRG) recorded a P/E ratio of 48.68 on October 15, 2026, with its stock trading at EUR 380.28 on October 16, 2026. The company's second-quarter 2026 revenue was USD 2.89 billion...

    ad-hoc-news.de•10/16/26•Somewhat-Bullish

    ISRG Ahead of Q3 Earnings: Can Procedure Growth Sustain Momentum?

    Intuitive Surgical (ISRG) is set to report Q3 2026 earnings, with expectations of continued adoption of robotic-assisted surgery platforms despite moderating U.S. procedure growth and competitive pressures in China....

    TradingView•10/16/26•Neutral

    CMR Surgical CEO outlines the path forward for Stryker’s robotics partnership

    CMR Surgical's CEO, Massimiliano Colella, discussed the company's strategic partnership with Stryker, focusing on a "slow to go big" approach for their Versius Plus system in the U.S. market. The $400 million deal will...

    MassDevice•10/16/26•Bullish

    SYK Valuation and Fair Value

    P/E
    21.0x
    Forward P/E
    16.5x
    EV/EBITDA
    17.1x
    P/FCF
    23.9x
    PEG
    1.3x
    P/B
    4.7x
    See GNG's fair value

    SYK Profitability: Margins, ROIC and FCF

    Gross margin
    65.0%
    Operating margin
    27.0%
    Net margin
    14.4%
    ROIC
    11.2%
    ROE
    16.5%
    FCF margin
    18.2%
    FCF yield
    4.2%

    SYK Competitors

    CompanyTicker
    CVS Health CorpCVS
    HCA Healthcare, Inc.HCA
    McKesson CorporationMCK
    Sanofi ADRSNY
    Medtronic PLCMDT
    GlaxoSmithKline PLC ADRGSK
    Bristol-Myers Squibb CompanyBMY
    Elevance Health IncELV

    Sector: Healthcare

    SYK Analyst Ratings

    Consensus
    Buy
    Analysts
    28
    Strong Buy
    7
    Buy
    15
    Hold
    6
    Sell
    0
    Strong Sell
    0

    SYK Bull Case vs Bear Case

    Bull case

    • SYK converts 18.2% of revenue into free cash flow.
    • SYK beat EPS estimates in 87.5% of its last 8 reported quarters.
    • 78.6% of SYK's analyst ratings are Buy or Strong Buy.

    SYK Earnings: Beat Rate and Next Report

    Beat rate
    7 of 8 quarters (87.5%)
    Average surprise
    1.3%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $3.56
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 12 down

    SYK Dividend

    Forward yield
    1.2%
    Payout ratio
    24.4%
    3Y DPS growth
    6.2%
    5Y DPS growth
    7.6%
    Pay months
    Jan, Apr, Jul, Oct
    SYK dividend history

    Frequently Asked Questions About SYK

    What is SYK's current dividend yield?

    Stryker Corporation (SYK) has a forward dividend yield of 1.20%.

    Does SYK pay dividends?

    Yes, Stryker Corporation pays dividends with a forward dividend yield of 1.20%.

    What is SYK's P/E ratio?

    Stryker Corporation has a price-to-earnings (P/E) ratio of 21.03.

    What is SYK's market cap?

    Stryker Corporation (SYK) has a market capitalization of $108.02B with a current stock price of $293.32.

    Related stocks

    Sector: Healthcare

    All stocks starting with S

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In